华法林起始治疗、心房颤动与肾功能:新诊断心房颤动老年患者中华法林的有效性与安全性比较
在加拿大阿尔伯塔省基于社区的回顾性队列研究中,纳入14,892名66岁及以上新诊断心房颤动且测量了肾功能的成人,采用倾向性评分匹配比较使用与未使用华法林者。结果显示,启动华法林治疗与所有肾功能分层中1年复合结局风险降低相关;仅eGFR 60-89 mL/min/1.73m²者大出血风险升高(HR 1.36,95%CI 1.13-1.64)。
要点
- 启动华法林与所有eGFR分层1年复合结局风险降低相关。
- 仅eGFR 60-89 mL/min/1.73m²者大出血风险升高(HR 1.36)。
- 研究为回顾性队列,存在选择偏倚。
核心结论
- 在老年心房颤动患者中,启动华法林治疗与所有肾功能分层中1年复合结局风险显著降低相关。
- 华法林相关大出血风险仅在接受eGFR 60-89 mL/min/1.73m²的患者中升高。
研究设计与样本
- 基于社区的回顾性队列研究,使用加拿大阿尔伯塔省全省实验室和行政数据(2003年5月1日至2012年3月31日)。
- 纳入14,892名66岁及以上新诊断心房颤动且测量了肾功能的成人,排除长期透析或肾移植患者。
- 采用倾向性评分构建匹配配对队列,匹配在诊断心房颤动前后60天内是否开具华法林处方的患者。
- 基线肾小球滤过率采用CKD-EPI肌酐方程估算,并按eGFR类别(≥90、60-89、45-59、30-44、<30 mL/min/1.73m²)进行匹配。
主要发现
- 与未使用华法林相比,启动华法林与复合结局风险降低相关,校正HR(95%CI)为:eGFR≥90组0.59(0.35-1.01)、60-89组0.61(0.54-0.70)、45-59组0.55(0.47-0.65)、30-44组0.54(0.44-0.67)、<30组0.64(0.47-0.87)。
- 与未使用华法林相比,华法林未与更高的大出血风险相关,但eGFR 60-89 mL/min/1.73m²组例外(HR 1.36,95%CI 1.13-1.64)。
关键数值与推荐
- 复合结局定义为全因死亡、缺血性卒中或短暂性脑缺血发作的复合终点(也分别评估)。
- 大出血定义为颅内、上消化道或下消化道或其他部位出血导致的首次住院或急诊就诊。
临床怎么用
- 原文未据此给出推荐。
局限性
- 选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effectiveness and safety of warfarin use among patients with atrial fibrillation (AF) and reduced kidney function are uncertain. STUDY DESIGN: Community-based retrospective cohort study (May 1, 2003, to March 31, 2012) using province-wide laboratory and administrative data in Alberta, Canada. SETTING & PARTICIPANTS: 14,892 adults 66 years or older with new AF and a measurement of kidney function. Long-term dialysis patients or kidney transplant recipients were excluded. PREDICTOR: Propensity scores were used to construct a matched-pairs cohort of patients with AF who did and did not have a warfarin prescription within a 60-day period surrounding their AF diagnosis. OUTCOMES: Within 1 year of initiating warfarin therapy (or the matched date for nonusers): (1) the composite of all-cause death, ischemic stroke, or transient ischemic attack (also assessed as separate end points) and (2) first hospitalization or emergency department visit for a major bleeding episode defined as an intracranial, upper or lower gastrointestinal, or other bleeding. MEASUREMENTS: Baseline glomerular filtration rate (GFR) was estimated using the CKD-EPI creatinine equation. Patients were matched within estimated GFR (eGFR) categories: ≥90, 60 to 89, 45 to 59, 30 to 44, and <30mL/min/1.73m2. Information for baseline characteristics (sociodemographics, comorbid conditions, and prescription drug use) was obtained. RESULTS: Across eGFR categories, warfarin therapy initiation was associated with lower risk for the composite outcome compared to nonuse (adjusted HRs [95% CI] for eGFR categories ≥ 90, 60-89, 45-59, 30-44, and <30mL/min/1.73m2: 0.59 [0.35-1.01], 0.61 [0.54-0.70], 0.55 [0.47-0.65], 0.54 [0.44-0.67], and 0.64 [0.47-0.87] mL/min/1.73m2, respectively). Compared to nonuse, warfarin therapy was not associated with higher risk for major bleeding except for those with eGFRs of 60 to 89mL/min/1.73m2 (HR, 1.36; 95% CI, 1.13-1.64). LIMITATIONS: Selection bias. CONCLUSIONS: Among older adults with AF, warfarin therapy initiation was associated with a significantly lower 1-year risk for the composite outcome across all strata of kidney function. The risk for major bleeding associated with warfarin use was increased only among those with eGFRs of 60 to 89mL/min/1.73m2.
引用
- Jun M, James MT, Ma Z, et al. Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation. Am J Kidney Dis. 2016. PMID: 27998624. doi:10.1053/j.ajkd.2016.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。